Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
Meredith Manning sold 45,249 shares of SLNO on 27 March at $67.04 per share, worth a total of $3.0M. They now own 52,932 SLNO shares, or a 50% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
